Tonix Pharmaceuticals announces proposed public offering of stock

Roth Capital Partners and Oppenheimer are bookrunners

By Angela McDaniels

Tacoma, Wash., July 13 – Tonix Pharmaceuticals Holding Corp. plans to offer shares of its common stock in an underwritten public offering.

Roth Capital Partners, LLC and Oppenheimer & Co. Inc. are acting as joint bookrunning managers with Janney Montgomery Scott LLC as co-manager, according to a company news release.

The company expects to use the proceeds for product development, working capital, general corporate purposes and possibly acquisitions of other companies, products or technologies, though no such acquisitions are currently planned.

Tonix is a New York-based pharmaceutical company developing medicines for central nervous system disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.